Algorae Pharmaceuticals Ltd (ASX:1AI) Share Price

Company Profile

Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUS
T: +61 422180317
https://www.algoraepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48

Recommended

Real estate share remains cheap despite losing airport legal battle.

Yingqi Tan, CFA | 12 June 2026

The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.

Jacob Robbins | 11 June 2026

We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.

Seth Goldstein, CFA | 11 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,006.10	29.10	0.32%
CAC 40	8,350.87	150.08	1.83%
DAX 40	24,635.30	425.59	1.76%
Dow JONES (US)	51,202.26	353.51	0.70%
FTSE 100	10,471.72	167.84	1.63%
HKSE	24,718.10	468.81	1.93%
NASDAQ	25,888.84	79.18	0.31%
Nikkei 225	66,020.04	1,802.77	2.81%
NZX 50 Index	13,393.87	191.71	1.45%
S&P 500	7,431.46	37.16	0.50%
S&P/ASX 200	8,804.00	30.50	0.35%
SSE Composite Index	4,031.51	44.50	1.12%